{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:51:17Z","timestamp":1770839477893,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clinthera.2024.06.018","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T06:56:44Z","timestamp":1723100204000},"page":"636-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Phase I Dose-Escalation Study of The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Polyethylene Glycol-Erythropoietin (PEG-EPO) in Healthy Subjects"],"prefix":"10.1016","volume":"46","author":[{"given":"Chaoying","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.06.018_bib0001","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1016\/S2352-3026(23)00160-6","article-title":"Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021","volume":"10","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.clinthera.2024.06.018_bib0002","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","article-title":"An update on the global disparities in kidney disease burden and care across world countries and regions","volume":"12","author":"Bello","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.clinthera.2024.06.018_bib0004","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000514550","article-title":"Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy","volume":"52","author":"Thurlow","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-981-13-8871-2_1","article-title":"Prevalence and disease burden of chronic kidney disease","volume":"1165","author":"Lv","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0007","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.15585\/mmwr.mm7111a3","article-title":"Reported cases of end-stage kidney disease\u2014United States, 2000\u20132019","volume":"71","author":"Burrows","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clinthera.2024.06.018_sbref0009","series-title":"IDF Diabetes Atlas","year":"2021"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0010","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0011","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13045-021-01202-2","article-title":"Burden of anemia and its underlying causes in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019","volume":"14","author":"Safiri","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0012","doi-asserted-by":"crossref","first-page":"e3872","DOI":"10.1097\/MD.0000000000003872","article-title":"Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study","volume":"95","author":"Li","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0013","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.clinthera.2024.06.018_bib0014","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0015","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0016","first-page":"56","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0017","unstructured":"Food and Drug Administration. Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease, 2011 (https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm259639.htm). Accessed April 08, 2017."},{"key":"10.1016\/j.clinthera.2024.06.018_bib0018","unstructured":"https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=5a4d762d72643cb695168a8c568aa7e3. Accessed April 15, 2012."},{"key":"10.1016\/j.clinthera.2024.06.018_bib0019","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1373\/clinchem.2005.053272","article-title":"Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies","volume":"51","author":"Moxness","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0020","first-page":"17","article-title":"International ethical guidelines for biomedical research involving human subjects","volume":"182","year":"2002","journal-title":"Bull Med Ethics"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0021","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0022","unstructured":"International Conference of Harmonization (ICH). ICH Tripartite Guideline for Good Clinical Practices E6 (R1), 1996 http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf. Accessed October 10, 1996."},{"key":"10.1016\/j.clinthera.2024.06.018_bib0023","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1523-1755.2005.00514.x","article-title":"Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients","volume":"68","author":"Kharagjitsingh","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0024","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0025","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","volume":"2014","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0026","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00730306","article-title":"Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease","volume":"1","author":"Macdougall","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2024.06.018_bib0027","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T10:48:12Z","timestamp":1725274092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824001930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0149291824001930"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Dose-Escalation Study of The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Polyethylene Glycol-Erythropoietin (PEG-EPO) in Healthy Subjects","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}